Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 7, 2010, Pages 1089-1099

  Xiao, Lan ^a   Yang, Yue Bo ^a   Li, Xiao Mao ^a   Xu, Cheng Fang ^a   Li, Tian ^a   Wang, Xiao Yun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

ATF 2; Endometrial carcinoma; Mitogen activated protein kinase pathway; PTEN; SB203580

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACTIVATING TRANSCRIPTION FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ACTIVATING TRANSCRIPTION FACTOR 2; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMIDAZOLES; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; PYRIDINES; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 77953230718     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0756-4     Document Type: Article

References (28)

1. Y Achiwa K Hasegawa Y Udagawa 2007 Regulation of the phosphatidy- linositol 3-kinase-Akt and the mitogen-activated protein kinase pathways by ursolic acid in human endometrial cancer cells Biosci Biotechnol Biochem 71 31 37 10.1271/bbb.60288 1:CAS:528:DC%2BD2sXhs1Wltrg%3D 17213663 (Pubitemid 46155142)
2. DV Bulavin AJ Fornace Jr 2004 p38 MAP kinase's emerging role as a tumor suppressor Adv Cancer Res 92 95 118 10.1016/S0065-230X(04)92005-2 1:CAS:528:DC%2BD2MXivVyhsbk%3D 15530558 (Pubitemid 39458114)
3. M Cully H You AJ Levine TW Mak 2006 Beyond PTEN mutations: the PI3K pathways as an integrator of multiple inputs during tumorigenesis Nat Rev Cancer 6 184 192 10.1038/nrc1819 1:CAS:528:DC%2BD28Xhslelt78%3D 16453012 (Pubitemid 43292562)
4. DeGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB, Hidalgo M (2004) Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 15:1510-1516
5. T Demuth LB Reavie JL Rennert M Nakada S Nakada DB Hoelzinger CE Beaudry AN Henrichs EM Anderson ME Berens 2007 MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival Mol Cancer Ther 6 1212 1222 10.1158/1535-7163.MCT-06-0711 1:CAS:528:DC%2BD2sXktFanu7c%3D 17406030 (Pubitemid 46711984)
6. JL Hecht GL Mutter 2006 Molecular and pathologic aspects of endometrial carcinogenesis J Clin Oncol 24 4783 4791 10.1200/JCO.2006.06.7173 1:CAS:528:DC%2BD28XhtFynsrrO 17028294 (Pubitemid 46630943)
7. L Hui L Bakiri E Stepniak EF Wagner 2007 p38α: a suppressor of cell proliferation and tumorigenesis Cell Cycle 6 2429 2433 1:CAS:528: DC%2BD2sXhsVahsbfF 17957136
8. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 10.3322/caac.20006 19474385
9. Z Jiang N Pore GJ Cerniglia R Mick MM Georgescu EJ Bernhard SM Hahn AK Gupta A Maity 2007 Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir Cancer Res 67 4467 4473 10.1158/0008-5472.CAN-06- 3398 1:CAS:528:DC%2BD2sXltVyrtr0%3D 17483362 (Pubitemid 46815097)
10. SS Joo Y-M Yoo 2009 Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer J Pineal Res 47 8 14 10.1111/j.1600-079X.2009.00682.x 1:CAS:528:DC%2BD1MXovVKgu7c%3D 19522739
11. AC Justin SG Eckhardt DR Camidge 2008 Targeted manipulation of apoptosis in cancer therapy Lancet 9 1002 1011 10.1016/S1470-2045(08)70209-2
12. S Kanda H Kanetake Y Miyata 2009 Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells J Cancer Res Clin Oncol 135 303 311 10.1007/s00432-008- 0465-4 1:CAS:528:DC%2BD1cXhsFejtbjF 18726116
13. 1/S checkpoint Mol Cell Biol 29 4341 4351 10.1128/MCB.00210-09 1:CAS:528:DC%2BD1MXhtVSju7jO 19528229
14. S Lee EJ Choi C Jin DH Kim 2005 Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line Gynecol Oncol 97 26 34 10.1016/j.ygyno.2004.11.051 1:CAS:528:DC%2BD2MXis1GrsL4%3D 15790433 (Pubitemid 40403670)
15. NR Leslie CP Downes 2004 PTEN function: how normal cells control it and tumour cells lose it Biochem J 382 1 11 10.1042/BJ20040825 1:CAS:528: DC%2BD2cXmsVChsLo%3D 15193142 (Pubitemid 39141560)
16. JS Lewis V Vijayanathan TJ Thomas RG Pestell C Albanese MA Gallo T Thomas 2005 Activation of cyclin D1 by estradiol and spermine in MCF-7 breast cancer cells: a mechanism involving the p38 MAP kinase and phosphorylation of ATF-2 Oncol Res 15 113 128 1:CAS:528:DC%2BD2MXmtleltbc%3D 16050133
17. F Meier B Schittek S Busch C Garbe K Smalley K Satyamoorthy G Li M Herlyn 2005 The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma Front Biosci 1 2986 3001 10.2741/1755
18. E Ortega RM Marti A Yeramian A Sorolla X Dolcet D Llobet L Abal M Santacana J Pallares A Llombart-Cussac X Matias-Guiu 2008 Targeted therapies in gynecologic cancers and melanoma Semin Diagn Pathol 25 262 273 10.1053/j.semdp.2008.07.008 19013892
19. D Pectasides E Pectasides T Economopoulos 2007 Systemic therapy in metastatic or recurrent endometrial cancer Cancer Treat Rev 33 177 190 10.1016/j.ctrv.2006.10.007 1:CAS:528:DC%2BD2sXitl2jtL0%3D 17196749 (Pubitemid 46343104)
20. G Pfeiler F Horn C Lattrich S Klappenberger O Ortmann O Treeck 2007 Apoptotic effects of signal transduction inhibitors on human tumor cells with different PTEN expression Oncol Rep 18 1305 1309 1:CAS:528:DC%2BD2sXhtlKhsrzI 17914589
21. HC Reinhardt AS Aslanian JA Lees MB Yaffe 2007 p53-Deficient cells rely on ATM-and ATR-mediated checkpoint signaling through the p38MAPK/MMK2 pathway for survival after DNA damage Cancer Cell 11 175 189 10.1016/j.ccr.2006.11.024 1:CAS:528:DC%2BD2sXitVartLc%3D 17292828 (Pubitemid 46209849)
22. M Ricote I García-Tuñón F Bethencourt B Fraile P Onsurbe R Paniagua M Royuela 2006 The p38 transduction pathway in prostatic neoplasia J Pathol 208 401 407 10.1002/path.1910 1:CAS:528:DC%2BD28XhvFOntbY%3D 16369914 (Pubitemid 43210527)
23. KJ Sales SA Milne AR Williams RA Anderson HN Jabbour 2004 Expression, localization, and signaling of prostaglandin F2 receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-activated protein kinase signaling pathways J Clin Endocrinol Metab 89 986 993 10.1210/jc.2003-031434 1:CAS:528: DC%2BD2cXhsFOjtbg%3D 14764825 (Pubitemid 38269922)
24. LS Steelman PM Navolanic ML Sokolosky JR Taylor BD Lehmann WH Chappell SL Abrams EW Wong KM Stadelman DM Terrian NR Leslie AM Martelli F Stivala M Libra RA Franklin JA McCubrey 2008 Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors Oncogene 27 4086 4095 10.1038/onc.2008.49 1:CAS:528: DC%2BD1cXnvFyrs7k%3D 18332865 (Pubitemid 351931994)
25. E Steiner O Eicher J Sagemüller M Schmidt H Pilch B Tanner JG Hengstler M Hofmann PG Knapstein 2003 Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University Int J Gynecol Cancer 13 197 203 10.1046/j.1525-1438.2003.13021.x 1:STN:280:DC%2BD3s7kt1eluw%3D%3D 12657124 (Pubitemid 37055478)
26. TM Thornton M Rincon 2009 Non-classical p38 MAP kinase functions: cell cycle checkpoints and survival Int J Biol Sci 5 44 51 1:CAS:528: DC%2BD1MXnsl2rtb4%3D 19159010
27. SA Vlahopoulos S Logotheti D Mikas A Giarika V Gorgoulis V Zoumpourlis 2008 The role of ATF-2 in oncogenesis BioEssays 30 314 327 10.1002/bies.20734 1:CAS:528:DC%2BD1cXltl2rs70%3D 18348191 (Pubitemid 351482329)
28. EF Wagner AR Nebreda 2009 Signal integration by JNK and p38 MAPK pathways in cancer development Nat Rev Cancer 9 537 549 10.1038/nrc2694 1:CAS:528:DC%2BD1MXovFymu7w%3D 19629069